Combination_Therapies_for_Personalised_Cancer_Medicine_in_EGFR_mutant_lung_cancer__WES-sc-4570
Combination_Therapies_for_Personalised_Cancer_Medicine_in_EGFR_mutant_lung_cancer__WES
This study involves mutagenizing a range of different cell lines with ENU to identify those mutations which engender resistance to targeted treatment.
In the last decade we have begun to move towards the use of targeted therapeutics in the clinic, often resulting in dramatic response rates in cancer patients. However, clinical experience has demonstrated time and time again that such responses are invariably followed by the development of drug resistance. Identification of the underlying mechanisms may enable us to reverse such resistance. Traditional methods of modelling this resistance in vitro can lead to a plethora of potential resistance mechanisms that can be difficult to decipher.